TT
The startup develops monoclonal antibody treatments targeting a new class of proteins involved in human mucosal inflammatory diseases. By inhibiting specific proteins implicated in the early inflammatory process, the company aims to enhance the resolution of inflammation and improve patient outcomes.
Updated 2 months ago
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops monoclonal antibody treatments targeting a new class of proteins involved in human mucosal inflammatory diseases. By inhibiting specific proteins implicated in the early inflammatory process, the company aims to enhance the resolution of inflammation and improve patient outcomes.